Pharma Journalist -

SAE Media Group reports: the Oligonucleotide Therapeutics Conference will touch on the Draft Guidance on CMC for Individualized ASO Therapies SAE Media Group proudly presents the…
Read More...

SAE Media Group reports: The full agenda and speaker line-up are now available to download for the 3rd Annual Wearable Injectors and Connected Devices Conference, returning in October…
Read More...

Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing…
Read More...

BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to…
Read More...

Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, and TSB…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio (mosunetuzumab),…
Read More...

Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center (“Moffitt”), a…
Read More...

Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with…
Read More...

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed…
Read More...

CureVac N.V. announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to…
Read More...